CAR T-Cell Therapy During the COVID-19 Pandemic - Episode 1

CAR T-Cell Therapy During the COVID-19 Pandemic

This OncLive® webinar will focus on the impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.


  • Resources for safe administration of CAR T-cell therapy
  • Patient selection for the receipt of CAR T-cell therapy in the COVID-19 setting
  • Supportive care and services for patients receiving therapy during the COVID-19 pandemic
  • Impact on the continuation and enrollment of clinical trials involving CAR T-cell therapies and implications for patients

Sponsored by: Novartis